Fresenius Kabi inaugurates €30 million expansion of transfusion and apheresis disposables plant in Dominican Republic

Top government and company officials joined local executives and employees as Fresenius Kabi inaugurated yesterday the major expansion of the company’s production site in the Dominican Republic.

In Haina, just outside the Dominican Republic’s capital and biggest city, Santo Domingo, the company manufactures apheresis sets. These products are used, for example, to collect blood components such as platelets or plasma. Fresenius Kabi undertook the expansion to meet the rising demand for these high-quality disposables used for critically important donations.

President Danilo Medina of the Dominican Republic was an honored guest at the ceremony. Also in attendance were Mats Henriksson, CEO of Fresenius Kabi, and Dr. Christian Hauer, President Transfusion Medicine and Cell Therapies Division of Fresenius Kabi.

Mats Henriksson highlighted that Fresenius Kabi is one of the leading international companies supplying transfusion medicines and cell therapies to blood services and hospitals.
"We are proud to continue and further develop our decades-long presence in this region, and we are very excited about this expanded facility,” Henriksson said. “This is yet another step in improving the lives of chronically and critically ill people around the world. We all look forward to putting ever more leading-edge disposables and devices in the hands of the people who are caring for patients and collecting life-saving plasma donations.”

Christian Hauer said the plant expansion will strengthen the company’s role as a major global exporter of apheresis and plasma collection sets. “Broadening our production activities in the Dominican Republic will increase our ability to produce and supply essential products for patients around the globe,” Hauer said.

Fresenius Kabi’s first plant building at the Haina site, which opened in 1987, covers around 18,000 square meters (195,000 square feet). The expansion, in which Fresenius Kabi is investing more than €30 million, doubles the size of the site’s newer, second plant building to around 15,000 square meters (160,000 square feet). The new space houses advanced production equipment, plasma kit assembly lines and sterilization units that double the cleanroom and storage capacity. The site also includes a large warehouse.

A global healthcare company specializing in life-saving medicines and technologies for infusion, transfusion and clinical nutrition, Fresenius Kabi has almost 40,000 employees worldwide, including more than 3,500 in Haina. The life-saving disposables for transfusion medicine and cell technologies manufactured in Haina are exported to global markets to make a difference in the quality of life of patients worldwide.

Note to the media: Images of the event can be found here.

---

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection and processing of blood and cell components.

Fresenius Kabi employs over 37,000 people worldwide. In 2018 the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

For more information visit the Company’s website at www.fresenius-kabi.com

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Mats Henriksson (Chairman), Marc Crouton, John Ducker, Dr. Oskar Haszonits,
Dr. Christian Hauer, Dr. Michael Schönhofen, Gerrit Steen
Chairman of the Supervisory Board: Stephan Sturm
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg - HRB 11654